Table 1:

Tocilizumab eligibility among patients admitted to hospital with COVID-19 between Jan. 1 and June 30, 2020, at 6 hospitals in Toronto and Mississauga, Ontario

CharacteristicNo. (%) of patients admitted to hospital with COVID-19*
OverallAged < 50 yrAged 50–59 yrAged 60–69 yrAged 70–79 yrAged > 79 yr
No. of hospital admissions820155 (18.9)126 (15.4)157 (19.1)164 (20.0)218 (26.6)
Age, yr; median (IQR)68 (54–80)40 (32–45)55 (53–57.75)64 (62–67)74 (72–77)86 (82–90)
Sex, female343 (41.8)53 (34.2)51 (40.5)56 (35.7)59 (36.0)124 (56.9)
No. of ICU admissions153 (18.7)25 (16.1)35 (27.8)41 (26.1)38 (23.2)14 (6.4)
Patients who died in hospital167 (20.4)≤ 5 (≤ 3.2)§9 (7.1)20 (12.7)37 (22.6)98 (45.0)
Patients who met the CRP criterion/CRP measured216 (50.8)
n = 425
40/91 (44.0)41/73 (56.2)35/78 (44.9)46/83 (55.4)54/100 (54.0)
Patients who met oxygenation criterion493 (60.1)58 (37.4)79 (62.7)87 (55.4)108 (65.9)161 (73.9)
Patients who were eligible for the tocilizumab RECOVERY trial primary estimate348 (42.4)42 (27.1)59 (46.8)68 (43.3)81 (49.4)98 (45.0)
Patients who were eligible for the tocilizumab RECOVERY trial lower bound estimate262 (32.0)33 (21.3)54 (42.9)53 (33.8)64 (39.0)58 (26.6)
Patients who were eligible for the tocilizumab RECOVERY trial upper bound estimate411 (50.1)44 (28.4)68 (54.0)75 (47.8)94 (57.3)130 (59.6)
Patients who were eligible for the tocilizumab RECOVERY trial complete data200 (47.1)
n = 425
25/91 (27.5)40/73 (54.8)35/78 (44.9)49/83 (59.0)51/100 (51.0)
Patients who were eligible for the tocilizumab REMAP-CAP trial268 (32.7)31 (20.0)44 (34.9)54 (34.4)61 (37.2)78 (35.8)
  • Note: CRP = C-reactive protein, ICU = intensive care unit, IQR = interquartile range, RECOVERY = Randomised Evaluation of COVID-19 Therapy, REMAP-CAP = Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia.

  • * Unless stated otherwise.

  • CRP level ≥ 75 mg/L at any point during their hospital stay.

  • Oxygen saturation on room air was < 92%, required oxygen therapy or intensive care. To provide a lower and upper bound on the tocilizumab eligibility estimate, we imputed all missing CRP results as < 75 and ≥ 75 mg/L, respectively.

  • § Exact number suppressed to reduce risk of patient reidentification.